Ovid Therapeutics (OVID) Accounts Payables (2016 - 2026)

Ovid Therapeutics' Accounts Payables history runs 11 years deep, the most recent figure standing at $8.9 million for Q1 2026.

• Quarterly Accounts Payables rose 355.18% year-over-year to $8.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.9 million (up 355.18% YoY) and the FY2025 annual result came in at $2.0 million, down 38.72% from the prior year.
• Accounts Payables was $8.9 million for Q1 2026 at Ovid Therapeutics, up from $2.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $8.9 million in Q1 2026 and bottomed at $1.0 million in Q3 2022.
• A 5-year average of $3.1 million and a median of $2.7 million in 2024 frame the typical range for Accounts Payables.
• Peak annual rise in Accounts Payables reached 407.58% in 2022, while the deepest fall reached 72.6% in 2022.
• Ovid Therapeutics' Accounts Payables stood at $2.0 million in 2022, then jumped by 89.61% to $3.7 million in 2023, then decreased by 13.8% to $3.2 million in 2024, then tumbled by 38.72% to $2.0 million in 2025, then surged by 353.78% to $8.9 million in 2026.
• Business Quant data shows OVID's Accounts Payables at $8.9 million in Q1 2026, $2.0 million in Q4 2025, and $1.7 million in Q3 2025.